Schuler Lab

Selected Publications

  1. O’Leary, K.A., D.E. Rugowski, M.P. Shea, R. Sullivan, A.R. Moser and L.A. Schuler. Prolactin synergizes with canonical Wnt signals to drive development of ER+ cancers via activation of the Notch pathway. Cancer Lett 503:231-239, 2021.
  2. Jallow, F., K.A. O’Leary, D.E. Rugowski, J.E. Guerrero, S.M. Ponik, and L.A. Schuler. Bidirectional interactions between the extracellular matrix and estrogen and antagonists, driving breast cancer progression, Oncogene 38: 6913-6915, 2019. Recognized by Extracellular Matrix News10.31 August 15, 2019, and Mammary Cell News 11.32 August 22, 2019; featured as Matrix Biology Highlight 87:8-9, 2020.
  3. Campbell, K.M., K.A. O’Leary, D.E. Rugowski, W.A. Mulligan, E.K. Barnell, Z.L. Skidmore, K. Krysiak, M. Griffith, L.A. Schuler, O.L. Griffith. Spontaneous aggressive ERα mammary tumor model is driven by Kras activation, Cell Reports 28:1526-1537, 2019. Recognized by Mammary Cell News11.31 August 15, 2019.
  4. Shea, M.P., K.A. O’Leary, S.A. Fakhraldeen, V. Goffin, A. Friedl, K.B. Wisinski, C.M. Alexander and L.A. Schuler. Anti-estrogen therapy increases plasticity and cancer stemness of prolactin-induced ERα+ mammary carcinomas. Cancer Res 78:1672-1684, 2018.
  5. Jallow, F., J.L. Brockman, K. Helzer, D. E. Rugowski, V. Goffin, E.T. Alarid, and L.A. Schuler. 17β-Estradiol and ICI 182,780 differentially regulate Stat5 isoforms in mammary epithelium, leading to distinct outcomes, J Endocr Soc 2:293-309, 2018.
  6. Shea, M.P., K.A. O’Leary, K.A. Wegner, C.M. Vezina, and L.A. Schuler. High collagen density augments mTOR-dependent cancer stem cells in ERα+ mammary carcinomas, and increases mTOR-independent lung metastases, Cancer Lett. 433:1-9, 2018.
  7. O’Leary, K.A., M.P. Shea, Salituro, C.E. Blohm and L.A. Schuler. Prolactin alters the mammary epithelial hierarchy, increasing progenitors and facilitating ovarian steroid action, Stem Cell Reports 9:1167–1179, 2017.
  8. Barcus C.E., K.A. O’Leary, J.L. Brockman, D.E. Rugowski, Y. Liu, N. Garcia, M. Yu, P.J. Keely, K.W. Eliceiri, L.A. Schuler. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res 19:1-13, 2017.
  9. Morgan M.M., B.P. Johnson, M.K. Livingston, L.A. Schuler, E.T. Alarid, K.E. Sung, D.J. Beebe. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. Pharmacol Ther, doi: 10.1016/j.pharmthera.2016.05.007
  10. Barcus C.E., P.J. Keely, K.W. Eliceiri, L.A. Schuler. Prolactin signals through focal adhesion complexes are increased by a stiff extracellular matrix environment in breast cancer cells, Oncotarget 7: 48093-48106, 2016. Top Story, Recognized by Extracellular Matrix News25 June 30, 2016
  11. O’Leary, K.A., M.P. Shea and L.A. Schuler. Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.  Adv. Expt. Med. Biol. 846:201-220, 2015.
  12. Barcus, C.E., E.C. Holt, P.J. Keely, K.W. Eliceiri, and L.A. Schuler. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS One. 2015 Jan 21;10(1):e0116891.
  13. Liu, Y., B.P. Johnson, A.L. Shen, J.A. Wallisser, K.J. Krentz, S.M. Moran, R. Sullivan, E. Glover, A.F. Parlow, N.R. Drinkwater, L.A. Schuler and C.A. Bradfield. Loss of Bmal1 in ovarian steroidogenic cells results in implantation failure in female mice, Proc. Natl. Acad. Sci. 111: 14295-14300, 2014. Highlighted in Nature Reviews Endocrinology 10:701, 2014.
  14. Arendt, L.M., D.E. Rugowski, T.A. Grafwallner-Huseth, M.J. Garcia-Barchino, H. Rui and L.A. Schuler. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer, Breast Cancer Research 13:R11, 2011. Recognized by the weekly Mammary Cell News.
  15. O’Leary, K.A., D.E. Rugowski, R. Sullivan and L.A. Schuler. Prolactin cooperates with loss of p53 to promote claudin low mammary carcinomas. Oncogene 33:3075-3082, 2014.
  16. Asher, J.M., K.A. O’Leary, D.E. Rugowski, L.M. Arendt and L.A. Schuler. Prolactin promotes mammary pathogenesis independently from cyclin D1, Am. J. Pathol. 181:294-302, 2012.
  17. O’Leary, K.A., F. Jallow, D.E. Rugowski, R. Sullivan, K.W. Sinkevicius, G.L. Greene and L.A. Schuler. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology 154:4883-4892, 2013.
  18. Barcus, C.E., P.J. Keely, K.W. Eliceiri and L.A. Schuler. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. J. Biol. Chem. 288:12722-12732, 2013.  Highlighted in Matrix Biol. 32:iii-iv, 2013; Recognized by the weekly Extracellular Matrix News.
  19. Yu, Z., L-X.Zhao, C. Jiang, Y. Duan, L. Wong, K.C. Carver, L.A. Schuler and B. Shen. Bafilomycins produced by endophytic actinomyces Streptomyces YIM56209, J. Antibiotics, 16: 159-162, 2011.
  20. Schuler, L.A. and A.P. Auger. Psychosocially influenced cancer: diverse early-life stress experiences and links to breast cancer. Cancer Prev Res 3:1365-1370, 2010.  (invited perspective)
  21. Sakamoto, K., A.A. Triplett, L.A. Schuler, K.-U. Wagner. Jak2 is required for the initiation but not maintenance of prolactin-induced mammary cancer, Oncogene 29: 5359-5369, 2010. Recognized by the weekly Mammary Cell News.
  22. Hasen, N.S., K.A. O’Leary, A.P. Auger and L.A. Schuler. Social isolation reduces mammary development, tumor incidence and expression of epigenetic regulators in wild type and p53-heterozygotic mice.  Cancer Prev Res, 3:620-629, 2010.
  23. Carver, K.C., T.M. Piazza and L.A. Schuler. Prolactin enhances IGF-IR phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J. Biol. Chem., 285:8003-8012, 2010.   Recognized by the weekly Mammary Cell News.
  24. Arendt, L.M., L.C. Evans, D.E. Rugowski, M.J. Garcia-Barchino, H. Rui, and L.A. Schuler. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes, J. Endocrinol. 203: 99-110, 2009. Cover feature.
  25. Regehr, K. J., M. Domenech, J.T. Koepsel, K. C. Carver, S. J. Ellison-Zelski, W. L. Murphy, L. A. Schuler, E. T. Alarid, and D. J. Beebe, Biological implications of polydimethylsiloxane-based microfluidic cell culture, Lab on a Chip 9: 2132-2139, 2009.
  26. Piazza, T.M., J-C. Lu, K.C. Carver and L.A. Schuler. Src family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells. Mol. Endocrinol. 23: 202-212, 2009.
  27. Arendt, L.M., T.L. Grafwallner-Huseth, and L.A. Schuler. Prolactin and growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression. Am. J. Pathol. 174:1065-1074, 2009.
  28. Carver, K.C., L.M. Arendt and L.A. Schuler. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol. Cell. Endocrinol. 307: 1-7, 2009.
  29. Arendt, L.M. and L.A. Schuler. Transgenic models to study actions of prolactin in mammary neoplasia. J. Mammary Gland Biol. Neoplasia 13:29-40, 2008.
  30. Carver, K.C. and L.A. Schuler. Prolactin does not require insulin-like growth factor (IGF) intermediates, but synergizes with IGF-I in human breast cancer cells. Mol. Cancer Res. 6:634-643, 2008.
  31. Arendt, L.M. and L.A. Schuler. Prolactin drives ERα-dependent ductal expansion and synergizes with TGFα to induce mammary tumors in males. Am. J. Pathol. 172:194-202, 2008.
  32. Gutzman, J.H., D.E. Rugowski, S.E. Nikolai, L.A. Schuler. Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin initiated signals in tumorigenesis dependent on cell context, Oncogene 26:6341-6348, 2007.
  33. Rose-Hellekant, T.A., M.D. Schroeder, J.L. Brockman, O. Zhdankin, R. Bolstad, K.S. Chen, M.N. Gould, L.A. Schuler, E.P. Sandgren. Estrogen receptor positive mammary tumorigenesis in TGFα transgenic mice progresses with progesterone receptor loss, Oncogene 26:5238-5246, 2007.
  34. Carnes M, Schuler L, Sarto GE, Lent SJ, Bakken L. Increasing sex and ethnic/racial diversity of researchers in aging: some promising strategies at the postdoctoral level. J. Am. Geriatr. Soc. 54:980-5, 2006.
  35. Arendt, L.M., T.A. Rose-Hellekant, E.P. Sandgren and L.A. Schuler. Prolactin potentiates TGFα induction of mammary neoplasia in transgenic mice, Am. J. Pathol.,168:1365-1374, 2006.
  36. Lu, J-C., T.M. Piazza, and L.A. Schuler. Proteasomes mediate prolactin-induced receptor downregulation and fragment generation in breast cancer cells, J. Biol. Chem. 280: 33909-33916, 2005.
  37. Brockman, J.L. and L.A. Schuler. Prolactin signals via Stat5 and Oct-1 to the proximal Cyclin D1 promoter, Mol. Cell. Endocrinol. 239: 45-53, 2005.
  38. Gutzman, J.H., S.E. Nikolai, D.E. Rugowski, J.J. Watters and L.A. Schuler. Prolactin and estrogen enhance the activity of Activating Protein-1 in breast cancer cells: role of ERK1/2 mediated signals to c-fos, Mol. Endocrinol. 19: 1765-1778, 2005.
  39. Gutzman, J.H., D.E. Rugowski, M.D. Schroeder, J.J. Watters and L.A. Schuler. Multiple kinase cascades mediate prolactin signals to Activating Protein-1 in breast cancer cells, Mol. Endocrinol. 18: 3064-3075, 2004.
  40. Gutzman, J.H., K.K. Miller and L.A. Schuler. Endogenous hPRL and not exogenous hPRL induces ERα and PRLR expression and increases estrogen responsiveness in breast cancer cells, J. Steroid Biochem. Mol. Biol. 88:69-877, 2004.
  41. Clevenger, C.V., P. Furth, S. Hankinson, and L.A. Schuler. The role of prolactin in mammary carcinoma. Endocrine Reviews 24:1-27, 2003.
  42. Schroeder, M.D., J.L. Brockman, A.M. Walker, and L.A. Schuler. Inhibition of PRL induced proliferative signals in mammary tumor cells by a molecular mimic of phosphorylated PRL, S179D-PRL, Endocrinology 144:5300-5307, 2003.
  43. Rose-Hellekant, T.A., L.M. Arendt, M.D. Schroeder, K. Gilchrist, E.P. Sandgren and L.A. Schuler. Prolactin induces ERα positive and ERα negative mammary cancer in transgenic mice, Oncogene 22:4664-4674, 2003.
  44. Lu, J.-C., Scott, P., Strous, G.J., and L.A. Schuler. Multiple internalization motifs differentially used by prolactin receptor isoforms mediate similar endocytic pathways, Mol. Endocrinol. 16: 774-784, 2002.
  45. Schroeder, M., J. Symowicz, and L.A. Schuler.  Prolactin modulates cell cycle regulators in mammary epithelial tumor cells, Mol. Endocrinol. 16:45-57, 2002.
  46. Brockman, J.L., M.D. Schroeder and L.A. Schuler. Prolactin stimulation of cyclin D1 transcription via the JAK-STAT pathway, Mol. Endocrinol. 16: 774-784, 2002.